← Back to patent-cliff list
Pumecitinib
Tier C — Watch / tradePumecitinib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：JAK1, JAK2
Indications (approved)：Seasonal allergic rhinitis, Allergic rhinitis, Atopic dermatitis, 痒疹
Regional status
US
-
EU
-
China
Phase III
2023-03-25
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pumecitinib?
Approved indications include: Seasonal allergic rhinitis, Allergic rhinitis, Atopic dermatitis, 痒疹.
When does the Pumecitinib patent expire?
No public expiry year is available for Pumecitinib yet; this page updates once verified.
How do I get a quote for Pumecitinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03